CAS NO: | 881681-01-2 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
生物活性 | Vonoprazan Fumarate (TAK-438), aproton pumpinhibitor (PPI), is a potent and orally activepotassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with anIC50of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease[1][2]. | ||||||||||||||||
IC50& Target | IC50: 19 nM (porcine gastric H+,K+-ATPase, at pH 6.5)[2] | ||||||||||||||||
体外研究 (In Vitro) | Vonoprazan (0.1 nM-10 μM; 30 minutes) exhibits porcine gastric H+,K+-ATPase activity in a concentration-dependent manner[2]. | ||||||||||||||||
体内研究 (In Vivo) | Vonoprazan (1-4 mg/kg; p.o.) completely inhibits basal and 2-deoxy-D-glucose (2DG, 200 mg/kg s.c.)-stimulated gastric acid secretion at the 4 mg/kg dose in rats[2].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 461.46 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C21H20FN3O6S | ||||||||||||||||
CAS 号 | 881681-01-2 | ||||||||||||||||
中文名称 | 富马酸沃诺拉赞 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(108.35 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|